13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839209
Total reported value
$3.8B
$3.8B
12 檔
14.6%
At the close of Q1 2024, Darwin Global Management, Ltd. disclosed equity holdings valued at approximately $3.8B, spread across 12 reported holdings.
During Q1 2024, Darwin Global Management, Ltd.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | Stock-Other | 25.02% | — | +374.31% | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 14.36% | — | +2390.49% | |
| 3 | KROS | Keros Therapeutics Inc | Stock-Other | 12.65% | — | +35.41% | |
| 4 | BHVN | Biohaven Ltd. | Stock-Other | 10.75% | — | — | |
| 5 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 10.46% | — | — | |
| 6 | BEAM | Beam Therapeutics Inc | Stock-Other | 9.32% | — | — | |
| 7 | APGE | Apogee Therapeutics Inc | Stock-Other | 7.36% | — | — | |
| 8 | XNCR | Xencor Inc | Stock-Other | 3.27% | — | — | |
| 9 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.39% | — | — | |
| 10 | ✓ | Elevation Oncology Inc | Stock-Other | 1.59% | — | — | |
| 11 | TRML | Tourmaline Bio Inc | Stock-Other | 1.42% | — | — | |
| 12 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.40% | — | — |
According to official SEC Form 13F filings, Darwin Global Management, Ltd. reported a total U.S. public equity portfolio value of $3.8B across 12 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PCVX, NUVL, KROS) accounted for 14.6% of total reported equity market value during Q1 2024.
During Q1 2024, Darwin Global Management, Ltd.'s top holdings by market value included PCVX (25.0%)、NUVL (14.4%)、KROS (12.7%). The largest single position, PCVX, represented 25.0% of total portfolio value.
In Q1 2024, Darwin Global Management, Ltd. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.